Voyager Therapeutics, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Voyager Therapeutics, Inc
Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Third Rock Ventures, LLC